Cutaneous Melanoma

Cutaneous melanoma is a malignant neoplasm arising from melanocytes, the pigment-producing cells of the skin. In veterinary medicine, it is a common tumor in dogs, particularly in haired skin, and less common in cats. The biological behavior varies significantly by anatomical location and species. In dogs, cutaneous melanomas of the haired skin are often benign, while those involving the oral cavity, nail bed, and mucocutaneous junctions are frequently malignant. In cats, cutaneous melanomas are generally more aggressive. The tumor can be classified as benign (melanocytoma) or malignant (melanoma) based on histological features, including cellular atypia, mitotic index, and presence of invasion. Surgical excision is the primary treatment, with wide margins recommended for malignant lesions. Staging is essential to detect regional lymph node and distant metastasis, which significantly impacts prognosis.

The exact etiology of cutaneous melanoma in animals is not fully understood, but several factors are implicated. Ultraviolet (UV) radiation exposure is a known risk factor in humans and is suspected to play a role in sun-exposed areas of lightly pigmented skin in animals, though evidence is less definitive. Genetic predisposition is significant, with certain breeds showing higher incidence, suggesting inherited mutations in genes such as BRAF, NRAS, or c-KIT. Chronic inflammation or trauma may contribute to malignant transformation in some cases. Viral etiologies have been proposed but not confirmed. In dogs, melanomas can arise de novo or from pre-existing melanocytic nevi. The molecular pathogenesis involves dysregulation of cell cycle control, apoptosis, and signaling pathways such as MAPK/ERK and PI3K/AKT, leading to uncontrolled proliferation and metastatic potential.

Cutaneous melanoma accounts for approximately 5-7% of all skin tumors in dogs and 1-2% in cats. In dogs, the median age at diagnosis is 9-11 years, with no strong sex predilection. Breeds with increased risk include Scottish Terriers, Airedale Terriers, Boston Terriers, Boxers, Golden Retrievers, and Miniature Schnauzers. Pigmented breeds like the Chow Chow and Shar-Pei may have a higher incidence of melanocytomas. In cats, melanoma is rare, but Siamese cats may be predisposed. Cutaneous melanomas in dogs are most commonly located on the head (especially eyelids, lips, and ears), trunk, and extremities. Malignant melanomas are more frequent in mucocutaneous junctions and nail beds. The biological behavior varies: in dogs, melanomas of the haired skin are benign in about 60-70% of cases, while oral and subungual melanomas are malignant in over 80% of cases. In cats, cutaneous melanomas are often malignant, with a high metastatic rate.

Melanomas arise from melanocytes in the basal layer of the epidermis or dermis. Malignant transformation involves genetic mutations that lead to uncontrolled cell proliferation, resistance to apoptosis, and acquisition of invasive and metastatic capabilities. Tumor growth is initially local, with expansion into the dermis and subcutaneous tissue. Malignant melanocytes invade blood vessels and lymphatics, leading to regional lymph node metastasis and distant spread to lungs, liver, and other organs. The tumor microenvironment, including immune cells and cytokines, plays a role in tumor progression and immune evasion. Histologically, malignant melanomas exhibit cellular pleomorphism, high mitotic index, nuclear atypia, and deep invasion. The mitotic index is a strong predictor of metastatic potential. In dogs, melanomas with a mitotic index of ≥3 per 10 high-power fields are considered malignant. The presence of tumor emboli and lymphatic invasion correlates with poor prognosis.

Intrinsic factors include age (older animals), breed predisposition (as listed), genetic susceptibility (e.g., mutations in tumor suppressor genes), and pigmentation status (lightly pigmented skin may be more susceptible to UV damage). Extrinsic factors include chronic sun exposure, especially in areas with sparse hair coat, and possibly chronic irritation or trauma. Prior history of skin lesions or immunosuppression may increase risk. In cats, Siamese breed and older age are risk factors. Obesity and hormonal factors have not been strongly linked. For malignant transformation, the presence of a pre-existing melanocytoma may be a risk factor, though most melanomas arise de novo.

Cutaneous melanomas present as pigmented (black, brown, or blue) nodules or plaques on the skin. They may be solitary or multiple. Benign melanocytomas are typically small, well-circumscribed, slow-growing, and non-ulcerated. Malignant melanomas often grow rapidly, may ulcerate, bleed, or become infected. They can be firm and fixed to underlying tissues. Clinical signs depend on location: eyelid melanomas may cause ocular irritation or blepharospasm; nail bed melanomas cause lameness, nail loss, or swelling of the digit. Systemic signs such as lethargy, weight loss, or respiratory distress may indicate metastasis. On physical examination, careful palpation of regional lymph nodes is essential to detect enlargement. Dermatologic examination should include assessment of size, color, texture, and presence of inflammation or necrosis.

Differential diagnoses for cutaneous melanoma include: 1) Melanocytoma (benign melanocytic tumor) - distinguished by histology: low mitotic index, no invasion. 2) Pigmented squamous cell carcinoma - arises from keratinocytes, often ulcerated, histopathology with keratin pearls. 3) Pigmented basal cell tumor - typically benign, histology shows basaloid cells. 4) Mast cell tumor - can be pigmented, but histology with metachromatic granules, positive for tryptase. 5) Hemangiosarcoma - vascular origin, histology with atypical endothelial cells, positive for factor VIII. 6) Histiocytoma - benign, self-limiting, histology with histiocytic infiltrate. 7) Fibrosarcoma - spindle cells, collagen production. 8) Sebaceous adenoma/carcinoma - differentiation with lipid vacuoles. 9) Trichoblastoma - hair follicle origin. 10) Metastatic neoplasia - history of primary tumor elsewhere. Definitive diagnosis requires histopathology or cytology.

The diagnostic workup for cutaneous melanoma follows a systematic approach: 1) Complete history and physical examination, including thorough skin and lymph node palpation. 2) Fine-needle aspiration (FNA) of the mass and any enlarged lymph nodes for cytology. Cytology may show melanin granules, but can be inconclusive. 3) Excisional or incisional biopsy for histopathology. Excisional biopsy with narrow margins is preferred for small lesions; incisional biopsy for large or ulcerated masses. 4) Histological evaluation to confirm diagnosis, assess malignancy (mitotic index, invasion), and surgical margins. 5) Staging: thoracic radiographs (3 views) to detect pulmonary metastasis; abdominal ultrasound if abdominal involvement suspected; lymph node aspiration or biopsy. 6) Advanced imaging (CT or MRI) for surgical planning, especially for large or invasive tumors. 7) Sentinel lymph node mapping may be considered for malignant melanomas. 8) Baseline blood work and urinalysis for surgical candidacy.

Complete blood count (CBC) may show mild anemia if chronic bleeding from ulcerated tumor. Biochemistry profile is usually unremarkable, but may reveal elevated liver enzymes if metastasis. Urinalysis is normal. Coagulation panel (PT/aPTT) is recommended before surgery, especially if wide excision is planned. Inflammatory biomarkers (CRP, SAA) may be elevated in malignant cases. Cytology of lymph node aspirates may show melanin-laden cells, but sensitivity is low. Histopathology is the gold standard; immunohistochemistry (e.g., Melan-A, PNL2, S100) can confirm melanocytic origin in amelanotic tumors.

Radiography: Thoracic radiographs (right and left lateral, ventrodorsal) are essential for staging; pulmonary metastases appear as well-defined nodules. For nail bed melanomas, radiographs of the digit may show osteolysis. Ultrasonography: Abdominal ultrasound for metastasis to liver, spleen, or lymph nodes. CT: Provides detailed anatomy for surgical planning, especially for head and neck tumors; can detect lymph node metastasis with contrast enhancement. MRI: Useful for evaluating deep soft tissue extension, especially in periorbital or nasal tumors. No specific imaging findings are pathognomonic for melanoma; imaging is primarily for staging and surgical planning.

Cytology: FNA of cutaneous melanoma often yields cells with variable melanin pigmentation, round to spindle shape, and prominent nucleoli. However, cytology cannot reliably differentiate benign from malignant. Histopathology: Excisional biopsy is evaluated for architectural pattern (nested, fascicular), cell morphology (epithelioid, spindle), pigmentation, nuclear atypia, mitotic count (per 10 HPF), and presence of ulceration, necrosis, and lymphatic invasion. Benign melanocytomas have low mitotic index (<3 per 10 HPF), no invasion, and well-differentiated cells. Malignant melanomas have high mitotic index, invasion into dermis/subcutis, and cellular pleomorphism. Immunohistochemistry: Melan-A, PNL2, and S100 are positive in melanocytic tumors; negative for cytokeratin (carcinoma) and CD18 (histiocytic). Surgical margins are assessed for completeness of excision.

Surgical excision is the treatment of choice for cutaneous melanoma. For benign melanocytomas, conservative excision with 1 cm margins is usually curative. For malignant melanomas, wide surgical excision with 2-3 cm lateral margins and one fascial plane deep is recommended. For nail bed melanomas, digit amputation (digitectomy) is often required. For eyelid melanomas, full-thickness wedge resection or cryotherapy may be considered. In cases of incomplete margins, re-excision or adjuvant radiation therapy is indicated. For metastatic disease, systemic therapy with tyrosine kinase inhibitors (e.g., toceranib phosphate) or immunotherapy (e.g., human melanoma vaccine) may be considered, though efficacy is variable. Chemotherapy (carboplatin, cisplatin) has limited efficacy. Palliative options include radiation therapy for pain control. Postoperative pain management includes opioids (e.g., hydromorphone 0.05-0.1 mg/kg IV q4-6h) and NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h). Antibiotics (e.g., cefazolin 22 mg/kg IV) are given perioperatively.

Prognosis for cutaneous melanoma in dogs depends on histological malignancy and location. Benign melanocytomas have an excellent prognosis with surgical cure. Malignant melanomas of the haired skin have a moderate prognosis; median survival time (MST) is approximately 1-2 years with surgery alone. Factors indicating poor prognosis include high mitotic index (≥3 per 10 HPF), ulceration, invasion, and presence of metastasis. Oral and subungual melanomas have a guarded prognosis, with MST of 6-12 months despite aggressive surgery. In cats, cutaneous melanomas are often malignant, with MST of 6-12 months. Negative prognostic indicators include large tumor size (>2 cm), lymph node metastasis, and distant metastasis. Complete surgical excision with clean margins improves prognosis.

Postoperative follow-up is crucial for early detection of recurrence or metastasis. Patients should be re-examined every 3 months for the first year, then every 6 months thereafter. Thoracic radiographs should be repeated every 3-6 months for the first 2 years. Surgical site should be monitored for local recurrence. For digit amputations, suture removal at 10-14 days. Activity restriction for 2 weeks post-surgery. Physical rehabilitation may be needed for limb function after digitectomy. Long-term monitoring includes complete physical examination and imaging as indicated.

Pearls: 1) Always submit excised masses for histopathology, even if cytology suggests benign. 2) For malignant melanomas, perform sentinel lymph node biopsy to guide staging. 3) Use a surgical marker to ensure adequate margins. 4) For eyelid melanomas, consider reconstructive techniques (e.g., H-plasty) to preserve eyelid function. Pitfalls: 1) Incomplete excision due to inadequate margins; always aim for 2-3 cm margins for malignant lesions. 2) Underestimating the aggressive nature of subungual melanomas; digit amputation is often necessary. 3) Failure to stage the patient, leading to missed metastasis. 4) Using electrocautery on the tumor, which can distort margins. 5) Not considering adjuvant therapy for high-risk tumors.

Perioperative antimicrobial prophylaxis: Cefazolin 22 mg/kg IV at induction, repeated every 90 minutes during surgery. Postoperative analgesia: Opioids (e.g., hydromorphone 0.05-0.1 mg/kg IV q4-6h) for 24-48 hours, then transition to oral opioids (e.g., tramadol 2-5 mg/kg PO q8-12h) or NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h, meloxicam 0.1 mg/kg PO q24h) for 3-5 days. For severe pain, consider a constant rate infusion (CRI) of fentanyl (2-5 mcg/kg/hr) or lidocaine (25-50 mcg/kg/min) and ketamine (0.5 mg/kg/hr). Local anesthesia: Lidocaine (2 mg/kg) or bupivacaine (1-2 mg/kg) as a local block at the surgical site. For adjunctive therapy in malignant melanoma: Toceranib phosphate (Palladia) 2.75 mg/kg PO every other day; monitor for gastrointestinal and hematologic side effects. Immunotherapy: Human melanoma vaccine (Oncept) is available for dogs with stage II-III oral melanoma; 2 mL SC every 2 weeks for 4 doses, then every 6 months. Chemotherapy: Carboplatin 300 mg/m² IV every 3 weeks for 4-6 cycles; may be considered for metastatic disease. Always adjust dosages based on renal and hepatic function.

Key studies: 1) Bostock (1979) demonstrated that mitotic index is a strong predictor of metastasis in canine melanomas. 2) Spangler and Kass (2006) reported that cutaneous melanomas in dogs have a lower metastatic rate than oral melanomas, with a 1-year survival rate of 80% for benign lesions. 3) Bergman et al. (2006) evaluated the human melanoma vaccine (Oncept) in dogs with oral melanoma, showing prolonged survival in stage II-III disease. 4) London et al. (2003) found that toceranib phosphate has activity against canine mast cell tumors, but its efficacy in melanoma is limited. 5) A retrospective study by Smith et al. (2002) on subungual melanomas reported a median survival of 12 months with digit amputation. 6) The ACVS consensus statement on surgical oncology recommends wide excision for malignant melanomas and sentinel lymph node biopsy for staging. 7) A meta-analysis by Giuliano et al. (2018) confirmed that mitotic index and tumor size are independent prognostic factors. 8) Recent studies on immunotherapy (e.g., anti-PD-1/PD-L1) are ongoing, showing promise in canine melanoma.